Michel, Maurice; Spinelli, Francesca; Grambihler, Annette et al.
Health-related quality of life in patients with autoimmune hepatitisQUALITY OF LIFE RESEARCH. Bd. 30. H. 10. 2021 S. 2853-2861
Graf, Christiana; Arncken, Jeannette; Lange, Christian M. et al.
Hepatic sarcoidosis: Clinical characteristics and outcomeJHEP REPORTS. Bd. 3. H. 6. 2021
Maehringer-Kunz, Aline; Meyer, Franziska I.; Hahn, Felix et al.
Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significanceUNITED EUROPEAN GASTROENTEROLOGY JOURNAL. Bd. 9. H. 5. 2021 S. 590-597
Czauderna, Carolin; Schmidtmann, Irene; Koch, Sandra et al.
High pretreatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinomaUNITED EUROPEAN GASTROENTEROLOGY JOURNAL. Bd. 9. H. 3. 2021 S. 388-397
Koessler, Thibaud; Alsina, Maria; Arnold, Dirk et al.
Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer groupBRITISH JOURNAL OF CANCER. Bd. 125. H. 7. 2021 S. 911-919
Stoehr, Fabian; Mueller, Lukas; Brady, Adrian et al.
How COVID-19 kick-started online learning in medical education-The DigiMed studyPLOS ONE. Bd. 16. H. 9. 2021
Ducreux, Michel; Zhu, Andrew X.; Cheng, Ann-Lii et al.
IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor).JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Zhu, Andrew X.; Finn, Richard; Ducreux, Michel et al.
IMbrave150: EXPLORATORY EFFICACY AND SAFETY OF ATEZOLIZUMAB (ATEZO) plus BEVACIZUMAB (BEV) VS SORAFENIB (SOR) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WITH NON-VIRAL ETIOLOGY IN A GLOBAL PHASE III STUDYHEPATOLOGY. Bd. 74. 2021 S. 646A-647A
Breder, Valeriy Vladimirovich; Vogel, Arndt; Merle, Philippe et al.
IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Finn, Richard S.; Qin, Shukui; Ikeda, Masafumi et al.
IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)SWISS MEDICAL WEEKLY. Bd. 151. 2021 S. 25-26